Pemivibart
Brand names: Pemgarda · Active ingredient: Pemivibart
In short: The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at l
What is Pemivibart used for?
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg):
Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2
and
Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments
and are unlikely to mount an adequate response to COVID-19 vaccination.
Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include:
Active treatment for solid tumor and hematologic malignancies
Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)
Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy
Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy)
Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich …
⚠ Boxed warning (FDA's strongest warning)
Anaphylaxis has been observed with PEMGARDA in 0.6% (4/623) of participants in a clinical trial.
Anaphylaxis was reported during the first and second infusion of PEMGARDA. (
5.1
,
6.1
)
Anaphylaxis can be life-threatening.
Prior to administering PEMGARDA, consider the potential benefit of COVID-19 prevention along with the risk of anaphylaxis. (
5.1
,
6.1,
14
)
Administer PEMGARDA only in settings in which healthcare providers have immediate access to medications to treat anaphylaxis and the ability to activate the emergency medical system (EMS), as necessary.
Clinically monitor individuals during the infusion and for at least two hours after completion of the infusion.
Discontinue PEMGARDA use permanently if signs or symptoms of anaphylaxis or any severe systemic reaction are observed and initiate appropriate medications and/or supportive therapy.
Pemivibart dosage
Initial Dosing:
The initial dosage of PEMGARDA in adults and adolescents (12 years of age and older weighing at least 40 kg) is 4500 mg administered as a single intravenous (IV) infusion
.
Repeat Dose:
The repeat dosage is 4500 mg of PEMGARDA administered as a single IV infusion every 3 months. Repeat dosing should be timed from the date of the most recent PEMGARDA dose.
The recommendations for dosing are based on the totality of the scientific evidence including clinical pharmacology data, antiviral activity data, and clinical study data
[see
Clinical Pharmacology (12.3
)
, Microbiology (12.4
), and Clinical Studies (14
)
].
No dosage adjustment is recommended in pregnant or lactating individuals, in geriatrics, or in individuals with renal or hepatic impairment
.
General Information:
PEMGARDA should be prepared and administered by a qualified healthcare provider using aseptic technique
.
Vials of PEMGARDA are for one-time use only.
Visually inspect the vials for particulate matter and discoloration. PEMGARDA is a clear to slightly opalescent, colorless to yellow solution. Discard the vial if the solution is cloudy, discolored, or if visible particles are observed.
PEMGARDA should be administered as an IV infusion diluted with 0.9% sodium chloride.
Materials Needed:
9 single-dose vials of PEMGARDA (125 mg/mL)
50 mL prefilled bag of 0.9% sodium chloride (normal saline) for IV injection
IV extension set with inline 0.2-micron filter
Infusion pump or gravity infusion set
0.9% sodium chloride injection for flushing
Preparation:
Remove PEMGARDA vials from refrigerated storage and allow to equilibrate to room temperature (18℃ to 26℃ [64℉ to 79℉]) for 10 minutes before preparation.
Do not expose to direct heat. Do not shake vials. Inspect the vials.
Prepare IV bag by removing and discarding 36 mL from a 50 mL prefilled bag of 0.9% sodium chloride for IV injection.
Withdraw 36 mL of PEMGARDA from nine (9) vials into appropriately sized polypropylene syringe(s) (e.g., one 40 mL syringe or two 20 mL syringes) and inject into prepared 0.9% sodium chloride IV bag.
The final product for administration will contain 50 mL: 36 mL of PEMGARDA and 14 mL of 0.9% sodium chloride.
This product is preservative-free and therefore should be administered immediately.
If immediate administration is not possible, the diluted solution may be stored at room temperature under ambient light for up to 4 hours. Do not shake the diluted solution.
Administration:
PEMGARDA should only be administered in settings in which healthcare providers have immediate access to medications to treat a severe hypersensitivity reaction, such as anaphylaxis, and the ability to activate the emergency medical system (EMS), as necessary
. …
How to take Pemivibart — instructions & advice from the label
As a prescribing healthcare practitioner, you must communicate to the patient, parent, and caregiver information consistent with the “FACT SHEET FOR PATIENTS, PARENTS OR CAREGIVERS” and provide them with a copy of this Fact Sheet prior to administration of PEMGARDA.
Anaphylaxis
Inform individuals that anaphylaxis has been observed with PEMGARDA. Advise individuals that they will be monitored during and for at least two hours after completion of the infusion. In those who experience signs or symptoms of anaphylaxis, PEMGARDA use will be discontinued permanently
.
Hypersensitivity and Infusion-Related Reactions
Inform individuals that hypersensitivity and infusion-related reactions have occurred during the infusion and up to 24 hours after the infusion with PEMGARDA. These hypersensitivity or infusion-related reactions may be severe or life threatening. Inform individuals that they will be monitored during and for at least two hours after completion of the infusion for signs and symptoms of hypersensitivity
.
Dosing
Inform individuals that they may need to receive additional doses of PEMGARDA every 3 months if ongoing protection is needed
. …
Warnings & precautions
Do not take this medicine if: PEMGARDA is contraindicated in individuals with previous severe hypersensitivity reactions, including anaphylaxis, to any component of PEMGARDA.
Anaphylaxis has been observed with PEMGARDA in 4 of 623 (0.6%) participants in a clinical trial
. Two participants had anaphylaxis during the first infusion, and two participants had anaphylaxis during the second infusion. Anaphylaxis can be life-threatening, and two of the anaphylactic reactions in the clinical trial were reported as life-threatening. Manifestations included pruritus, flushing, urticaria, erythema, angioedema, diaphoresis, dizziness, tinnitus, wheezing, dyspnea, chest discomfort, and tachycardia. In all 4 cases, PEMGARDA was permanently discontinued.
Prior to administering PEMGARDA, consider the potential benefit of COVID-19 prevention along with the risk of anaphylaxis
.
Administer PEMGARDA only in settings in which healthcare providers have immediate access to medications to treat anaphylaxis and the ability to activate the emergency medical system (EMS), as necessary.
Clinically monitor individuals during the 60-minute infusion and for at least two hours after completion of the infusion. If signs or symptoms of an anaphylactic reaction occur, immediately discontinue administration, and initiate appropriate medications and/or supportive therapy. Discontinue PEMGARDA use permanently in individuals who experience signs or symptoms of anaphylaxis
.
Hypersensitivity and infusion-related reactions occurring during the infusion and up to 24 hours after the infusion have been observed with administration of PEMGARDA. Hypersensitivity or infusion-related reactions may be severe or life threatening. …
Pemivibart side effects
The following adverse reactions have been observed in the clinical study of PEMGARDA that supported the EUA
. The adverse reaction rates observed in the clinical study cannot be directly compared to rates in the clinical studies of other products and may not reflect the rates observed in clinical practice. Additional adverse reactions associated with PEMGARDA may become apparent with more widespread use.
The safety of PEMGARDA is based on exposure of 623 participants who received at least one dose of PEMGARDA 4500 mg IV in one of two cohorts in the ongoing CANOPY trial. Cohort A is a single-arm, open-label trial in adults who have moderate-to-severe immune compromise (n=306), while Cohort B is a randomized, placebo-controlled trial in which adults who do not have moderate-to-severe immune compromise received PEMGARDA (n=317) or placebo (n=162). In Cohort A, 297 participants received a second dose of PEMGARDA 4500 mg IV three months after the initial dose. In Cohort B, 296 participants received a second dose of PEMGARDA 4500 mg IV and 154 received a second dose of placebo three months after the initial dose.
Anaphylaxis
Anaphylaxis was observed in 4 of 623 (0.6%) participants in CANOPY, all in Cohort A.
Two participants had anaphylaxis during the first infusion, and two participants had anaphylaxis during the second infusion. All four reactions led to permanent discontinuation of PEMGARDA. …
Drug interactions
Drug-drug interaction studies have not been performed. PEMGARDA is not renally excreted or metabolized by cytochrome P450 enzymes; therefore, interactions with concomitant medications that are renally excreted or that are substrates, inducers, or inhibitors of cytochrome P450 enzymes are unlikely
.
About this medicine
Pemivibart is a human IgG1 mAb produced by a Chinese Hamster Ovary cell line and has a molecular weight of 147.51 kDa.
PEMGARDA (pemivibart) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to yellow solution for intravenous infusion after dilution. Each 4 mL of solution contains 500 mg of pemivibart, glycine (33.03 mg), L-arginine hydrochloride (63.2 mg), L‑histidine (3.67 mg), L-histidine hydrochloride monohydrate (3.43 mg), L-methionine (5.97 mg), polysorbate 80 (1.2 mg), sterile water for injection (USP). The pH is 6.2.
How it works: Pemivibart is a SARS-CoV-2 antiviral drug . Available data suggest a positive relationship between serum neutralizing antibody titers and COVID-19 pre-exposure-prophylactic efficacy using clinical data (completed prior to the emergence of Omicron and Omicron lineage VOCs) and drug concentration data of neutralizing human monoclonal antibodies against SARS-CoV-2. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 0bdc20a9-791f-9a06-e063-6394a90a84cc. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate